• Publications
  • Influence
Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.
Novel cell therapies derived from human T lymphocytes are exhibiting enormous potential in early-phase clinical trials in patients with hematologic malignancies. Ex vivo modification of T cells isExpand
Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.
Gene editing can be used to overcome allo-recognition, which otherwise limits allogeneic T cell therapies. Initial proof-of-concept applications have included generation of such "universal" T cellsExpand
Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy.
In the Guillain-Barré syndrome subform acute motor axonal neuropathy (AMAN), Campylobacter jejuni enteritis triggers the production of anti-ganglioside Abs (AGAbs), leading to immune-mediated injuryExpand
Generation of human islet-specific regulatory T cells by TCR gene transfer.
Based on the success in animal models of type 1 diabetes (T1D), clinical trials of adoptive regulatory T cell (Treg) therapy are underway using ex vivo expanded polyclonal Tregs. However,Expand
Automated Lentiviral Transduction of T Cells with Cars Using the Clinimacs Prodigy
BACKGROUND Genetically modified T cells have enormous potential for the treatment of relapsed and refractory haematopoietic malignancies. CD19-positive B-cell malignancies including acuteExpand
Automated Manufacture of CAR19 Donor Lymphocytes Incorporated into an Escalated Dose DLI Protocol: Preliminary Results from the CARD Study
Introduction: Clinical studies of 2nd generation CD19 Chimeric Antigen Receptor (CAR) T-cells have delivered unprecedented clinical responses in patients with B-ALL. Increasing demand for CAR T-cellsExpand
455. Automated Lentiviral Transduction of T Cells with CARS Using the CliniMACS Prodigy
T lymphocytes are exhibiting enormous potential in early phase clinical trials in patients with haematological malignancies. However, the complex procedures involved in the ex-vivo modification of TExpand
Abstract CT105: AUTO1, a novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL
Introduction: CD19 CAR T therapy has advanced treatment of relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (B-ALL). However, several challenges remain including: (1) considerable toxicity ofExpand